Virtual Library
Start Your Search
Qingming Shi
Author of
-
+
P2.01 - Advanced NSCLC (ID 618)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:00 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.01-011 - The Efficiency and Safety of Apatinib plus S-1 as Second-Line or Laterline Chemotherapy for Advanced Squamous Cell Lung Carcinoma (ID 8136)
09:00 - 09:00 | Presenting Author(s): Qingming Shi
- Abstract
Background:
There is no standard treatment strategy for patients with advanced squamous cell lung carcinoma who experienced progression with one or more lines of chemotherapy. Apatinib, a new tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2), has been shown confirming antitumor activity and manageable toxicities in gastric cancers and other solid tumor. Moreover, clinical trials of S-1 on squamous cell lung carcinoma shows curative effect and lighter adverse reactions. This prospective study tried to investigate the efficacy and safety of apatinib plus S-1 as second- or third-line treatment in patients with advanced squamous cell lung carcinoma.
Method:
In this open-label single-arm study(ChiCTR-OPC-16009048), patients were treated oral apatinib, at a dose of 250-500 mg daily, and S-1, at a dose of 60mg/m[2] daily D1-14, repeat every 3 weeks, in the second- or third-line setting. The primary endpoint was progression-free-survival (PFS) and the tumor response was determined according to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. Treatment was continued until disease progression or unacceptable toxicity occurs.
Result:
From August 19, 2016 to May 31, 2017, 16 patients were enrolled. In 16 patients, there were 7 patients available for efficiency evaluation and 12 patients available for safety evaluation. Computed tomography (CT) scan evaluation revealed that partial response (PR) occurred in 1 of 7 patients and other 6 showed stable disease (SD). However with 2 patients of 6 patients showed stable disease (SD), the tumor demonstrates central cavitation. Hypertension is one of the most frequent adverse reactions, which appeared in 3 of 12 patients who were getting to be normal under oral antihypertensive agent. Others like hand-foot syndrome, proteinuria, diarrhea and fatigue appeared in 1 of 12 patients respectively and could be better controlled. No treatment-related hemorrhage occurred.
Conclusion:
Apatinib plus S-1 exhibits superior activity and acceptable toxicity for evaluable patients with advanced squamous cell lung carcinoma. The research team will continue the study.
